Novavax Inc At Devex UNGA 76 Transcript

Sep 21, 2021 / 12:50PM GMT
Jenny Lei Ravelo -

Hello, everyone. I'm Jenny Lei Ravelo, Senior Global Health Reporter for Devex. Thank you so much for tuning into our series of events around the UN General Assembly. Access to COVID-19 vaccines continues to be a hot topic and rightly so. Billions of people around the world still have not received at least one dose of the COVID vaccine. There continues to be a huge demand. And despite estimates of vaccines being producing over 1 billion a month, access to them, particularly in low and middle income countries, remains a challenge. But there are more vaccines coming, and one of them is actually a COVID-19 vaccine developed by Novavax, an American biotech company that has decades of experience developing vaccines for serious infectious diseases.

In June, Novavax grabbed headlines after releasing efficacy data from a Phase III clinical trial in the U.S., showing those COVID-19 vaccine has 90% overall efficacy, including 100% protection against moderate and severe illness.

And so I'm pleased to be joined today by Mr. John Trizzino, Novavax' Executive Vice President, Chief

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
4.6 out of 5 Trustpilot